Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccination
Following severe adverse reactions to the AstraZeneca ChAdOx1-S-nCoV-19 vaccine 1 , 2 , European health authorities recommended that patients under the age of 55 years who received one dose of ChAdOx1-S-nCoV-19 receive a second dose of the Pfizer BNT162b2 vaccine as a booster. However, the effective...
Saved in:
| Published in: | Nature (London) 2021-12, Vol.600 (7890), p.701-706 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|